Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP6 | P55212 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | RORC | P51449 | 15/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.45 |
| ▸ | RORB | Q92753 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13278385 | 0.87 | PIK3CD (0.44) | MAPT | |
| SCHEMBL15448633 | 0.82 | ALDH1A1 (0.56) | GFERMEN1MAPTKMT2A | |
| SCHEMBL30409743 | 0.82 | MAPT (0.53) | MEN1MAPTKMT2APDK2 | |
| SCHEMBL12692664 | 0.82 | MAPT (0.53) | MEN1MAPTKMT2APDK2 | |
| SCHEMBL5262415 | 0.81 | GFER (0.55) | CASP6GFERMEN1MAPTKMT2A | |
| SCHEMBL28123361 | 0.80 | ALDH1A1 (0.59) | MEN1MAPTKMT2A | |
| SCHEMBL17002237 | 0.79 | GFER (0.62) | CASP6GFERMEN1MAPTKMT2A | |
| SCHEMBL159816 | 0.79 | ALDH1A1 (0.58) | MEN1MAPTKMT2A | |
| SCHEMBL20644395 | 0.78 | PIK3CD (0.47) | MEN1MAPTKMT2A | |
| SCHEMBL30270109 | 0.78 | PIK3CD (0.47) | MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970116-A1 | ARYL SULFAMIDE AND SULFAMATE DERIVATIVES AS RORc MODULATORS | F. Hoffmann-La Roche AG (CH) | 2016-01-20 | — | — | EP | disclosed |
| US-9216988-B2 | Benzyl sulfonamide derivatives as RORc modulators | GENENTECH, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216988-B2 | Benzyl sulfonamide derivatives as RORc modulators | GENENTECH, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216988-B2 | Benzyl sulfonamide derivatives as RORc modulators | GENENTECH, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-8912219-B2 | Aryl sulfamide and sulfamate derivatives as RORc modulators | GENENTECH, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912219-B2 | Aryl sulfamide and sulfamate derivatives as RORc modulators | GENENTECH, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-8912219-B2 | Aryl sulfamide and sulfamate derivatives as RORc modulators | GENENTECH, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| EP-2794584-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-10-29 | — | — | EP | disclosed |
| WO-2014140059-A1 | ARYL SULFAMIDE AND SULFAMATE DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014140059-A1 | ARYL SULFAMIDE AND SULFAMATE DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275032-A1 | ARYL SULFAMIDE AND SULFAMATE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275032-A1 | ARYL SULFAMIDE AND SULFAMATE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275032-A1 | ARYL SULFAMIDE AND SULFAMATE DERIVATIVES AS RORc MODULATORS | GENENTECH, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20130190288-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORC MODULATORS | GENENTECH, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190288-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORC MODULATORS | GENENTECH, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2013092941-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013092941-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190288-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORC MODULATORS | RORA, RORC, RORB | CASP6 3085/4885GFER 3478/4885MEN1 3375/4885 |
| US-20140275032-A1 | ARYL SULFAMIDE AND SULFAMATE DERIVATIVES AS RORc MODULATORS | RORA, RORC, RORB | CASP6 3387/4885GFER 1494/4885MEN1 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.